Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Larder

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
The Journal of Infectious Diseases|November 22, 2000
Despite high concordance, distinct mutational and phenotypic drug resistance profiles in human immunodeficiency virus type 1 RNA are observed in gastrointestinal mucosal biopsy specimens and peripheral blood mononuclear cells compared with plasmaM A Poles, J Elliott, J Vingerhoets, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|June 1, 1995
Emergence and clinical relevance of mutations associated with zidovudine resistance in asymptomatic HIV-1 infected patientsE J Calderón, Y Torres, F J Medrano, et al.
Antiviral Therapy|June 10, 2000
HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohortV Miller, A Cozzi-Lepri, K Hertogs, et al.
AIDS Research and Human Retroviruses|February 15, 2001
Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease geneF Dronda, J L Casado, S Moreno, et al.
AIDS (London, England)|October 8, 1999
Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community settingP R Harrigan, K Hertogs, W Verbiest, et al.
Journal of Virology|September 18, 2001
Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 proteinS Peters, M Muñoz, S Yerly, et al.
AIDS (London, England)|March 9, 2000
Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimenJ L Casado, K Hertogs, L Ruiz, et al.
Journal of Clinical Microbiology|July 16, 1999
Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphismsM Vahey, M E Nau, S Barrick, et al.
AIDS (London, England)|January 12, 2001
Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failureV Miller, C Sabin, K Hertogs, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 8, 2001
Resistance to antiretroviral therapy among patients in UgandaP J Weidle, C M Kityo, P Mugyenyi, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
The Journal of Infectious Diseases|November 22, 2000
Despite high concordance, distinct mutational and phenotypic drug resistance profiles in human immunodeficiency virus type 1 RNA are observed in gastrointestinal mucosal biopsy specimens and peripheral blood mononuclear cells compared with plasmaM A Poles, J Elliott, J Vingerhoets, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|June 1, 1995
Emergence and clinical relevance of mutations associated with zidovudine resistance in asymptomatic HIV-1 infected patientsE J Calderón, Y Torres, F J Medrano, et al.
Antiviral Therapy|June 10, 2000
HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohortV Miller, A Cozzi-Lepri, K Hertogs, et al.
AIDS Research and Human Retroviruses|February 15, 2001
Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease geneF Dronda, J L Casado, S Moreno, et al.
AIDS (London, England)|October 8, 1999
Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community settingP R Harrigan, K Hertogs, W Verbiest, et al.
Journal of Virology|September 18, 2001
Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 proteinS Peters, M Muñoz, S Yerly, et al.
AIDS (London, England)|March 9, 2000
Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimenJ L Casado, K Hertogs, L Ruiz, et al.
Journal of Clinical Microbiology|July 16, 1999
Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphismsM Vahey, M E Nau, S Barrick, et al.
AIDS (London, England)|January 12, 2001
Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failureV Miller, C Sabin, K Hertogs, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 8, 2001
Resistance to antiretroviral therapy among patients in UgandaP J Weidle, C M Kityo, P Mugyenyi, et al.
Pageof 4